Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy




Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

Campaign urges healthcare providers to harness the versatile power of electric fields to outsmart solid tumors

ROOT, Switzerland–(BUSINESS WIRE)–$NVCR #TumorTreatingFieldsTherapy–Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an emerging cornerstone of solid tumor treatment. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.

With a poor survival outlook across many solid tumors, physicians and patients need additional treatment strategies that utilize innovative modalities. Novocure’s educational campaign includes a new website and aims to build awareness around key elements of TTFields therapy, including its versatile modality, its multimechanistic action and its potential for versatile clinical application across solid tumors as shown in preclinical studies. The TTFields therapy campaign uses the iconography of the Queen, the most powerful and versatile piece of the chess board, to highlight the clinical versatility of this innovative anticancer modality.

“We’re excited to launch this campaign to drive awareness and help the oncology community understand the science of Tumor Treating Fields,” said Novocure’s Chief Commercial Officer Pritesh Shah. “Broadening understanding of our therapy is key in bringing Tumor Treating Fields therapy to more patients who can benefit globally.”

To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.

About Tumor Treating Fields

TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts

Investors:
Ingrid Goldberg

investorinfo@novocure.com
610-723-7427

Media:
Leigh Labrie

media@novocure.com
610-723-7428